In the ongoing LiPlaCis phase 1 study cancer patients are treated with liposomal cisplatin an intelligent technology where cisplatin is encapsulated in lipid bubble that opens when it meets a specific enzyme called sPLA2 at the tumor site. The primary goal is to increase the efficacy of the drug. The DRP uses data from the individual patients own tumor to define whether the patient will be sensitive to LiPlaCis and can be included in the study.
About LiPlasome Pharma and LiPlaCis
LiPlasome(TM) Pharma ApS is developing LiPlaCis®, a lipid-based, nano-encapsulated cisplatin drug candidate, designed to selectively target cancer cells and complemented by a proprietary drug response companion diagnostic. LiPlaCis exhibits greater potency and an increased maximum tolerated dose (MTD) compared to cisplatin alone, and will soon progress to a phase 1 / phase 2 extension trial in metastatic breast cancer, having already exhibiting early efficacy in phase 1. LiPlaCis incorporates proprietary targeted lipasome technology, leveraging a novel lipid-based nanoparticle chemistry to address limitations of earlier generation cisplatin formulations; through liposome disruption via tumour selective phospholipase A2-IIA isoenzyme (sPLA2-IIA) hydrolysis, optimised stability and enhanced drug payload capacity and delivery. The LiPlaCis companion diagnostic (Drug Response Predictor) accelerates and de-risks future clinical development and is positioned to provide a value-added commercial diagnostic opportunity.
MPI’s lead product DRP (Drug Response Predictor) is a tool to develop tumor-derived gene signatures that may predict which cancer patients are high likely responders to a given anticancer product. The DRP has been tested in 24 trials where 20 trials were positive. The DRP has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center.
The DRP method can also be used to design the Clinical Development Plan i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patient’s gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients who have a high likelihood of response to the drug. The DRP method can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US in 2013.
MPI’s proprietary method can predict patients sensitivity towards a given anticancer drug by its Drug Response Prediction a gene-tests on tumours. MPI’s customers are Pharma and biotech engaged in developing anticancer drugs. MPI’s technology has derived from data from more than 3.000 patient’s tumours and are validated in 24 clinical studies. The test is broadly applicable in all cancer types and for almost all anticancer therapies. The test is believed to be of high value especially for the very large group of cancer patients for whom there are no other bio-markers available.